• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

地塞米松与调整体重后的甲基泼尼松龙治疗中重度 SARS-CoV-2 肺炎患者的比较。

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia.

机构信息

Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España; Instituto de Investigación Biosanitaria ibs.Granada, Granada, España.

Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España.

出版信息

Med Clin (Barc). 2023 Feb 24;160(4):156-159. doi: 10.1016/j.medcli.2022.06.015. Epub 2022 Jul 20.

DOI:10.1016/j.medcli.2022.06.015
PMID:35987733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9296504/
Abstract

OBJECTIVES

To compare the 30-day outcome (mortality and/or ICU admission) of patients admitted for moderate-severe SARS-CoV-2 pneumonia treated with dexamethasone after the Recovery study versus those treated with weight-adjusted methylprednisolone.

METHODS

Retrospective cohort study of 65 patients with moderate-severe pneumonia who received dexamethasone 6 mg/day (DXM group) versus 80 treated with weight-adjusted methylprednisolone (MTPN group).

RESULTS

Twenty-one (32.3%) patients in the DXM group died vs. 8 (10%) in the MTPN group (p-value < 0.001) and 29 (44.6%) in the DXM group required ICU admission vs. 2 (2.5%) of the MTPN group (p-value < 0.001). There were no baseline differences regarding sociodemographic characteristics with a higher mean qSOFA in the MTPN group. The hazard ratio for mortality and ICU admission adjusted for age, sex, and admission CRP was 2.189 (1.082-4.426; 95% CI) and 10.589 (2.139-48.347; 95% CI) for the DXM group, respectively, vs. MTPN group.

CONCLUSIONS

Mortality and admission to the ICU were lower in patients treated with weight-adjusted methylprednisolone compared to those treated with dexamethasone.

摘要

目的

比较在康复研究后接受地塞米松治疗的中重度 SARS-CoV-2 肺炎患者与接受体重调整甲基泼尼松龙治疗的患者的 30 天结局(死亡率和/或 ICU 入院)。

方法

回顾性队列研究了 65 名接受地塞米松 6 毫克/天(DXM 组)与 80 名接受体重调整甲基泼尼松龙(MTPN 组)治疗的中重度肺炎患者。

结果

DXM 组有 21 名(32.3%)患者死亡,而 MTPN 组有 8 名(10%)(p 值<0.001),DXM 组有 29 名(44.6%)患者需要入住 ICU,而 MTPN 组有 2 名(2.5%)(p 值<0.001)。两组在社会人口统计学特征方面没有基线差异,但 MTPN 组的平均 qSOFA 较高。在校正年龄、性别和入院 CRP 后,死亡和 ICU 入院的风险比分别为 DXM 组的 2.189(1.082-4.426;95%CI)和 10.589(2.139-48.347;95%CI),而 MTPN 组则为 1.082(0.554-2.139;95%CI)。

结论

与接受地塞米松治疗的患者相比,接受体重调整甲基泼尼松龙治疗的患者死亡率和 ICU 入院率较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c81a/9296504/fee20dd015e7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c81a/9296504/fee20dd015e7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c81a/9296504/fee20dd015e7/gr1_lrg.jpg

相似文献

1
Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia.地塞米松与调整体重后的甲基泼尼松龙治疗中重度 SARS-CoV-2 肺炎患者的比较。
Med Clin (Barc). 2023 Feb 24;160(4):156-159. doi: 10.1016/j.medcli.2022.06.015. Epub 2022 Jul 20.
2
Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia.中度至重度新型冠状病毒肺炎患者中地塞米松与体重调整剂量甲泼尼龙的比较。
Med Clin (Engl Ed). 2023 Feb 24;160(4):156-159. doi: 10.1016/j.medcle.2023.01.002. Epub 2023 Jan 24.
3
Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.地塞米松与甲泼尼龙大剂量治疗新冠肺炎肺炎。
PLoS One. 2021 May 25;16(5):e0252057. doi: 10.1371/journal.pone.0252057. eCollection 2021.
4
Association between different corticosteroid regimens used in severe SARS-CoV-2 infection and short-term mortality: retrospective cohort study.严重 SARS-CoV-2 感染中使用的不同皮质类固醇方案与短期死亡率之间的关联:回顾性队列研究。
Rev Esp Anestesiol Reanim (Engl Ed). 2024 May;71(5):379-386. doi: 10.1016/j.redare.2024.02.012. Epub 2024 Feb 21.
5
High-dose pulse methylprednisolone vs. dexamethasone standard therapy for severe and critical COVID-19 pneumonia: Efficacy assessment in a retrospective single-centre experience from Malaysia.大剂量脉冲甲泼尼龙与地塞米松标准疗法治疗重症和危重症 COVID-19 肺炎:来自马来西亚单中心回顾性经验的疗效评估。
Med J Malaysia. 2024 Jan;79(1):15-20.
6
Effect of pulse methylprednisolone on prognosis in SARS-CoV-2 patients with severe pneumonia.脉冲甲基泼尼松龙对重症 COVID-19 肺炎患者预后的影响。
Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):1234-1240. doi: 10.26355/eurrev_202402_35362.
7
Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients.甲基强的松龙输注与地塞米松在新型冠状病毒肺炎急性呼吸窘迫综合征机械通气患者中的比较。
Egypt J Intern Med. 2022;34(1):19. doi: 10.1186/s43162-022-00113-z. Epub 2022 Feb 15.
8
Dexamethasone versus methylprednisolone for multiple organ dysfunction in COVID-19 critically ill patients: a multicenter propensity score matching study.地塞米松与甲泼尼龙治疗 COVID-19 危重症患者多器官功能障碍:一项多中心倾向评分匹配研究。
BMC Infect Dis. 2024 Feb 13;24(1):189. doi: 10.1186/s12879-024-09056-y.
9
Comparison of methylprednisolone pulse vs conventional dexamethasone for adult cases of COVID-19 requiring oxygen; a Japanese retrospective cohort study.比较甲泼尼龙脉冲与常规地塞米松治疗需要吸氧的成人 COVID-19 病例:一项日本回顾性队列研究。
J Infect Chemother. 2023 Mar;29(3):269-273. doi: 10.1016/j.jiac.2022.11.008. Epub 2022 Nov 24.
10
A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19.COVID-19 重症监护患者中甲基强的松龙与地塞米松的比较。
J Intensive Care Med. 2021 Jun;36(6):673-680. doi: 10.1177/0885066621994057. Epub 2021 Feb 25.

本文引用的文献

1
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性(COV-BARRIER):一项随机、双盲、平行分组、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1.
2
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.早期使用依那西普联合可溶性尿激酶型纤溶酶原激活物受体血浆水平指导 COVID-19 治疗:一项双盲、随机对照 3 期试验。
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
3
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.在患有严重SARS-CoV-2肺炎且炎症较轻的患者中,单独使用糖皮质激素与单独使用托珠单抗或糖皮质激素加托珠单抗的比较。
Med Clin (Engl Ed). 2021 Jun 25;156(12):602-605. doi: 10.1016/j.medcle.2021.01.004. Epub 2021 May 24.
4
Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.地塞米松与甲泼尼龙大剂量治疗新冠肺炎肺炎。
PLoS One. 2021 May 25;16(5):e0252057. doi: 10.1371/journal.pone.0252057. eCollection 2021.
5
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
6
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.静脉注射用免疫球蛋白 γ 治疗严重新型冠状病毒病 2019:一项随机安慰剂对照双盲临床试验。
BMC Infect Dis. 2020 Oct 21;20(1):786. doi: 10.1186/s12879-020-05507-4.
7
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响:CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
8
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联:一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
9
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
10
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.